Journal of Blood & Lymph

Multiple Myeloma

Multiple myeloma is a cancer that forms in a type of white blood cell called as plasma cell. Plasma cells helps you fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Apart from producing helpful antibodies, the cancer cells produce abnormal proteins that can cause kidney problems.

Related Journals of Multiple Myeloma

Journal of Blood & Lymph, Leukemia, Insights in Blood Pressure, Hypertension: Open Access, Hypo & Hyperglycemia, Clinical Lymphoma, Myeloma & Leukemia, Hematology and Leukemia, Leukemia, Leukemia and Lymphoma, Leukemia Research, Leukemia Supplements, The Open Leukemia Journal.

High Impact List of Articles

• Commentary: A New Marker for Tumor-Reactive T Cells in Acute Myeloid Leukemia
  Yihan Mei*

  Commentary: Journal of Blood & Lymph, 2024: 332

• Commentary: A New Marker for Tumor-Reactive T Cells in Acute Myeloid Leukemia
  Yihan Mei*

  Commentary: Journal of Blood & Lymph, 2024: 332

• Commentary on “Crosstalk between DNA Damage Repair and Metabolic Regulation in Hematopoietic Stem Cells’’
  Peiwen Fei*

  Commentary: Journal of Blood & Lymph, 2024: 335

• Commentary on “Crosstalk between DNA Damage Repair and Metabolic Regulation in Hematopoietic Stem Cells’’
  Peiwen Fei*

  Commentary: Journal of Blood & Lymph, 2024: 335

• Concatenate Omics with Drug Repurposing: A Proposed Workflow
  Angelos Giannakoulas, Marios Nikolaidis, Grigorios D. Amoutzias and Nikolaos Giannakoulas*

  Commentary: Journal of Blood & Lymph, 2024: 329

• Concatenate Omics with Drug Repurposing: A Proposed Workflow
  Angelos Giannakoulas, Marios Nikolaidis, Grigorios D. Amoutzias and Nikolaos Giannakoulas*

  Commentary: Journal of Blood & Lymph, 2024: 329

• Cytotoxic Non-T_H2 CD4⁺ T Cells are associated with Asthma Severity
  Sara Herrera-De La Mata, Syed Hasan Arshad, Ramesh J Kurukulaaratchy and Grégory Seumois*

  Mini Review: Journal of Blood & Lymph, 2024: 328

• Cytotoxic Non-T_H2 CD4⁺ T Cells are associated with Asthma Severity
  Sara Herrera-De La Mata, Syed Hasan Arshad, Ramesh J Kurukulaaratchy and Grégory Seumois*

  Mini Review: Journal of Blood & Lymph, 2024: 328

• Pomalidomide treatment enhances survival in myeloma patients via immune modulation
  Rao Prabhala*, Hannah Seah, Vaishnavi Bade and Srikanth Talluri

  Commentry: Journal of Blood & Lymph, 2024: 323

• Pomalidomide treatment enhances survival in myeloma patients via immune modulation
  Rao Prabhala*, Hannah Seah, Vaishnavi Bade and Srikanth Talluri

  Commentry: Journal of Blood & Lymph, 2024: 323

• Potential Respiratory Complications in Multiple Myeloma Patients Undergoing Percutaneous Vertebroplasty May Include Non-Thrombotic Pulmonary Embolism
  Michael L. Scharf*

  Commentary: Journal of Blood & Lymph, 2024: 321

• Potential Respiratory Complications in Multiple Myeloma Patients Undergoing Percutaneous Vertebroplasty May Include Non-Thrombotic Pulmonary Embolism
  Michael L. Scharf*

  Commentary: Journal of Blood & Lymph, 2024: 321

• Demographic Profile, Risk Stratification, Clinical Characteristics, and Treatment Outcome of Patients with Multiple Myeloma: A Five-Year Retrospective Study at a Tertiary Hospital in Ethiopia
  Ephrem Haile*, Adugna Tasew, Amha Gebremedhin, Abdulaziz Sherif and Fissehatsion Tadesse

  Research Article: Journal of Blood & Lymph, 2023: 311

• Demographic Profile, Risk Stratification, Clinical Characteristics, and Treatment Outcome of Patients with Multiple Myeloma: A Five-Year Retrospective Study at a Tertiary Hospital in Ethiopia
  Ephrem Haile*, Adugna Tasew, Amha Gebremedhin, Abdulaziz Sherif and Fissehatsion Tadesse

  Research Article: Journal of Blood & Lymph, 2023: 311

• Commentary on TP53 Mutated Myeloid Malignancies and Their Treatment Strategy
  Yasuhito Nannya*

  Commentary: Journal of Blood & Lymph, 2023: 306

• Commentary on TP53 Mutated Myeloid Malignancies and Their Treatment Strategy
  Yasuhito Nannya*

  Commentary: Journal of Blood & Lymph, 2023: 306

• Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data
  Merve Keskin*

  Research Article: Journal of Blood & Lymph, 2023: 299

• Comparison of Transcriptomic Changes in Younger and Older Multiple Myeloma Patients from the MMRF-CoMMpass Study RNA-Seq Data
  Merve Keskin*

  Research Article: Journal of Blood & Lymph, 2023: 299

• A System Biology Perspective to Overcoming the Challenges of JAK Inhibition Mon Therapy for Myeloproliferative Neoplasms: An Overview
  Alphonsus Ogbonna Ogbuabor*, Peter Uwadiegwu Achukwu, Silas Anayo Ufelle and Daniel Chukwuemeka Ogbuabor

  Commentary: Journal of Blood & Lymph, 2021: 260

• A System Biology Perspective to Overcoming the Challenges of JAK Inhibition Mon Therapy for Myeloproliferative Neoplasms: An Overview
  Alphonsus Ogbonna Ogbuabor*, Peter Uwadiegwu Achukwu, Silas Anayo Ufelle and Daniel Chukwuemeka Ogbuabor

  Commentary: Journal of Blood & Lymph, 2021: 260

• Molecular Epidemiology of BCR-ABL Rearrangement Variants in Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia from Major Institute of Pakista
  Zeeshan Ansar Ahmed, Muhammad Shariq Shaikh, Muhmmad Hasan Hayat, Hamayail Ansari, Huzaifa Bin Rashid, Tariq Moatter and Zeeshan Ansar Ahmed*

  Research Article: Journal of Blood & Lymph, 2021: 261

• Molecular Epidemiology of BCR-ABL Rearrangement Variants in Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia from Major Institute of Pakista
  Zeeshan Ansar Ahmed, Muhammad Shariq Shaikh, Muhmmad Hasan Hayat, Hamayail Ansari, Huzaifa Bin Rashid, Tariq Moatter and Zeeshan Ansar Ahmed*

  Research Article: Journal of Blood & Lymph, 2021: 261

Conference Proceedings